PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CRL vs. XLV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between CRL and XLV is 0.49, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

CRL vs. XLV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Charles River Laboratories International, Inc. (CRL) and Health Care Select Sector SPDR Fund (XLV). The values are adjusted to include any dividend payments, if applicable.

600.00%700.00%800.00%900.00%1,000.00%AugustSeptemberOctoberNovemberDecember2025
643.18%
590.55%
CRL
XLV

Key characteristics

Sharpe Ratio

CRL:

-0.53

XLV:

0.20

Sortino Ratio

CRL:

-0.58

XLV:

0.34

Omega Ratio

CRL:

0.93

XLV:

1.04

Calmar Ratio

CRL:

-0.31

XLV:

0.17

Martin Ratio

CRL:

-0.87

XLV:

0.46

Ulcer Index

CRL:

22.58%

XLV:

4.64%

Daily Std Dev

CRL:

37.33%

XLV:

10.97%

Max Drawdown

CRL:

-69.81%

XLV:

-39.17%

Current Drawdown

CRL:

-64.32%

XLV:

-10.11%

Returns By Period

In the year-to-date period, CRL achieves a -11.43% return, which is significantly lower than XLV's 1.90% return. Both investments have delivered pretty close results over the past 10 years, with CRL having a 9.28% annualized return and XLV not far behind at 8.91%.


CRL

YTD

-11.43%

1M

-10.24%

6M

-25.08%

1Y

-22.89%

5Y*

0.46%

10Y*

9.28%

XLV

YTD

1.90%

1M

2.54%

6M

-4.42%

1Y

2.17%

5Y*

7.77%

10Y*

8.91%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CRL vs. XLV — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRL
The Risk-Adjusted Performance Rank of CRL is 2222
Overall Rank
The Sharpe Ratio Rank of CRL is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of CRL is 1818
Sortino Ratio Rank
The Omega Ratio Rank of CRL is 1818
Omega Ratio Rank
The Calmar Ratio Rank of CRL is 2727
Calmar Ratio Rank
The Martin Ratio Rank of CRL is 2727
Martin Ratio Rank

XLV
The Risk-Adjusted Performance Rank of XLV is 1010
Overall Rank
The Sharpe Ratio Rank of XLV is 1010
Sharpe Ratio Rank
The Sortino Ratio Rank of XLV is 99
Sortino Ratio Rank
The Omega Ratio Rank of XLV is 99
Omega Ratio Rank
The Calmar Ratio Rank of XLV is 1313
Calmar Ratio Rank
The Martin Ratio Rank of XLV is 1010
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CRL vs. XLV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and Health Care Select Sector SPDR Fund (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CRL, currently valued at -0.53, compared to the broader market-2.000.002.004.00-0.530.20
The chart of Sortino ratio for CRL, currently valued at -0.58, compared to the broader market-4.00-2.000.002.004.00-0.580.34
The chart of Omega ratio for CRL, currently valued at 0.93, compared to the broader market0.501.001.502.000.931.04
The chart of Calmar ratio for CRL, currently valued at -0.31, compared to the broader market0.002.004.006.00-0.310.17
The chart of Martin ratio for CRL, currently valued at -0.87, compared to the broader market-10.000.0010.0020.00-0.870.46
CRL
XLV

The current CRL Sharpe Ratio is -0.53, which is lower than the XLV Sharpe Ratio of 0.20. The chart below compares the historical Sharpe Ratios of CRL and XLV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
-0.53
0.20
CRL
XLV

Dividends

CRL vs. XLV - Dividend Comparison

CRL has not paid dividends to shareholders, while XLV's dividend yield for the trailing twelve months is around 1.64%.


TTM20242023202220212020201920182017201620152014
CRL
Charles River Laboratories International, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XLV
Health Care Select Sector SPDR Fund
1.64%1.67%1.59%1.47%1.33%1.49%2.17%1.58%1.47%1.60%1.43%1.35%

Drawdowns

CRL vs. XLV - Drawdown Comparison

The maximum CRL drawdown since its inception was -69.81%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for CRL and XLV. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-64.32%
-10.11%
CRL
XLV

Volatility

CRL vs. XLV - Volatility Comparison

Charles River Laboratories International, Inc. (CRL) has a higher volatility of 10.00% compared to Health Care Select Sector SPDR Fund (XLV) at 3.59%. This indicates that CRL's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%AugustSeptemberOctoberNovemberDecember2025
10.00%
3.59%
CRL
XLV
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab